Vaginally administered anti-dysrhythmic agents for treating pelvic pain
First Claim
1. A pharmaceutical vaginal composition for treating or preventing pelvic pain, or for treating or improving infertility, associated with uterine dysrhythmia comprising a therapeutically effective amount of an anti-dysrhythmic treating agent and a pharmaceutically acceptable extended-release bioadhesive carrier.
4 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to a pharmaceutical composition for relieving pelvic pain or infertility associated with uterine dysrhythmia. The composition includes a locally-administered anti-dysrhythmic treating agent and a bioadhesive extended-release carrier. The composition may be delivered in an extended release formulation that includes a bioadhesive, water-swellable, water-insoluble, cross-linked polycarboxylic acid polymer, such as polycarbophil. The treating agent may be a local anesthetic, such as lidocaine. The invention also relates to a method of treating or preventing pelvic pain, or treating or improving infertility, by inserting a mixture of an anti-dysrhythmic treating agent and a bioadhesive carrier into the vagina of the patient to be treated.
-
Citations
27 Claims
- 1. A pharmaceutical vaginal composition for treating or preventing pelvic pain, or for treating or improving infertility, associated with uterine dysrhythmia comprising a therapeutically effective amount of an anti-dysrhythmic treating agent and a pharmaceutically acceptable extended-release bioadhesive carrier.
- 10. A pharmaceutical vaginal composition for treating or preventing pelvic pain, or for treating or improving infertility, associated with uterine dysrhythmia comprising a therapeutically effective amount of a local anesthetic treating agent and a pharmaceutically acceptable extended-release bioadhesive carrier.
- 14. A method of treating or preventing pelvic pain, or for treating or improving infertility, comprising vaginally administering a composition that comprises a therapeutically effective amount of an anti-dysrhythmic treating agent and a pharmaceutically acceptable bioadhesive carrier that releases the treating agent over an extended period of time after administration.
- 25. A pharmaceutical vaginal composition for treating or preventing uterine dysrhythmia comprising a pharmaceutically acceptable extended-release bioadhesive carrier and one or more treating agents selected from the group consisting of coronary anti-arrhythmic, local anesthetics, calcium channel blocker, autocoid agents, prostaglandin blockers, non-steroidal anti-inflammatory drugs, COX inhibitors, thromboxane synthase inhibitors, and leukotriene inhibitors.
-
27. The composition of claim 27 wherein the polymer is polycarbophil and the one or more treating agents include lidocaine.
Specification